Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.67 |
| ▸ | FPR2 | P25090 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | CTSS | P25774 | 2/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.59 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039089 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL7044299 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL9716776 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL9716778 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL7317573 | 0.95 | HDAC8 (0.64) | ATMITGB3ITGA2BFPR2HDAC8 | |
| SCHEMBL14684392 | 0.95 | HDAC8 (0.64) | ATMITGB3ITGA2BFPR2HDAC8 | |
| SCHEMBL8569421 | 0.92 | ALDH1A1 (0.65) | ATMITGB3ITGA2BKMT2AHDAC8 | |
| SCHEMBL10706226 | 0.92 | ATM (0.60) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL2406036 | 0.92 | ALDH1A1 (0.65) | ATMITGB3ITGA2BKMT2AHDAC8 | |
| SCHEMBL11059108 | 0.91 | CTSL (0.60) | ATMITGB3ITGA2BFPR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| CN-107001259-A | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-3186224-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2016030310-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-0950046-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-04-10 | — | — | EP | disclosed |
| EP-0543858-B1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIOTECH PHARM (GB) | 2000-12-20 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| EP-0288176-A1 | Tyrosine derivatives and use thereof | AJINOMOTO CO., INC. (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0126974-B1 | CARBOXYALKYL PEPTIDE DERIVATIVES | G.D. Searle & Co. (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4568666-A | COLLAGENASE INHIBITORS, ANTIARTJRITIC AGENTS | G. D. SEARLE & CO. (US) | 1986-02-04 | — | — | US | disclosed |
| EP-0159396-A2 | Carboxyalkyl peptide derivatives | G.D. Searle & Co. (US) | 1985-10-30 | — | — | EP | disclosed |
| US-4511504-A | COLLAGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1985-04-16 | — | — | US | disclosed |
| EP-0126974-A1 | Carboxyalkyl peptide derivatives | G.D. Searle & Co. (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | ATM 2199/4885ITGB3 4573/4885ITGA2B 4075/4885 |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HTR1B, MTNR1B, DRD2 | ATM 2199/4885ITGB3 4573/4885ITGA2B 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.